董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jon Congleton | 男 | Independent Director | 62 | 未披露 | 未持股 | 2026-04-30 |
| Heather Turner | 女 | Board Chair and Director | 53 | 4.00万美元 | 4.87 | 2026-04-30 |
| Kate Haviland | 女 | Independent Director | 50 | 未披露 | 0.55 | 2026-04-30 |
| Erin Lavelle | 女 | Independent Director | 48 | 2.50万美元 | 3.84 | 2026-04-30 |
| David Friedman | 男 | Independent Director | 51 | 未披露 | 未持股 | 2026-04-30 |
| Lyn Baranowski | 女 | Chief Executive Officer,Director and President | 50 | 205.67万美元 | 96.87 | 2026-04-30 |
| Jill Carroll | 女 | Independent Director | 50 | 未披露 | 未持股 | 2026-04-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lyn Baranowski | 女 | Chief Executive Officer,Director and President | 50 | 205.67万美元 | 96.87 | 2026-04-30 |
| Howard M. Lazarus | 男 | Chief Medical Officer | 60 | 74.09万美元 | 19.21 | 2026-04-30 |
| Douglas Carlson | 男 | Chief Business Officer and Chief Financial Officer | 47 | 90.59万美元 | 15.61 | 2026-04-30 |
| Melissa Rhodes | 女 | Chief Operating Officer | 48 | 96.75万美元 | 15.04 | 2026-04-30 |
| Adam Golden | 男 | General Counsel | 62 | 未披露 | 未持股 | 2026-04-30 |
董事简历
中英对照 | 中文 | 英文- Jon Congleton
-
Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
Jon Congleton has been a member of Immunic, Inc.'s Board since March 2026. Mr. Congleton has served as President and Chief Executive Officer and as a member of the board of directors of Mineralys Therapeutics, Inc. ("Mineralys") since November 2020. Prior to joining Mineralys, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries Ltd. (Teva), where for over 18 years, he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University. - Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
- Jon Congleton has been a member of Immunic, Inc.'s Board since March 2026. Mr. Congleton has served as President and Chief Executive Officer and as a member of the board of directors of Mineralys Therapeutics, Inc. ("Mineralys") since November 2020. Prior to joining Mineralys, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries Ltd. (Teva), where for over 18 years, he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.
- Heather Turner
-
Heather Turner自2019年12月起担任Lyell Immunopharma, Inc.的首席总法律顾问，该职位从2019年4月至2019年12月任职。Heather Turner曾担任Orexigen Therapeutics, Inc.（一家上市公司）的高级副总裁、总法律顾问兼秘书。在此之前，她曾担任 Conor Medsystems, Inc.（一家上市公司）企业副总法律顾问，并是Cooley LLP律师事务所的合伙人。
Heather Turner has been the chair of Avalyn Pharma Inc.'s board of directors since October 2024. Ms. Turner has served as Chief Executive Officer of LB Pharmaceuticals Inc. (Nasdaq: LBRX), a clinical stage biopharmaceutical company since November 2024. Prior to joining LB Pharmaceuticals, Ms. Turner was President and Chief Executive Officer of Carmot Therapeutics Inc., or Carmot (acquired by Roche) from January 2023 to June 2024 and Chief Operating Officer from September 2022 to December 2022. Prior to Carmot, Ms. Turner served as Chief Legal Officer at Lyell Immunopharma, Inc. from April 2019 to May 2022. Prior to Lyell, Ms. Turner served as Executive Vice President, General Counsel and Secretary of Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a publicly traded gene therapy and gene editing company, from February 2018 to March 2019, and served as Executive Vice President, General Counsel, Secretary, and Head of Portfolio Strategy at Atara Biotherapeutics, Inc. (Nasdaq: ATRA), or Atara, a publicly traded allogeneic cell therapy company, from September 2016 to February 2018 and as Vice President and General Counsel of Atara from June 2015 to September 2016. Prior to that, Ms. Turner served as General Counsel and Secretary at Orexigen Therapeutics, Inc. a company focused on metabolic diseases, from June 2007 to June 2015. Ms. Turner has served as a member of the board of directors of Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical stage biopharmaceutical company, since November 2024. Ms. Turner started her career at Cooley LLP as a corporate securities associate. Ms. Turner received her J.D. from UCLA School of Law and her B.A. in Environmental Studies from the University of California, Santa Barbara. - Heather Turner自2019年12月起担任Lyell Immunopharma, Inc.的首席总法律顾问，该职位从2019年4月至2019年12月任职。Heather Turner曾担任Orexigen Therapeutics, Inc.（一家上市公司）的高级副总裁、总法律顾问兼秘书。在此之前，她曾担任 Conor Medsystems, Inc.（一家上市公司）企业副总法律顾问，并是Cooley LLP律师事务所的合伙人。
- Heather Turner has been the chair of Avalyn Pharma Inc.'s board of directors since October 2024. Ms. Turner has served as Chief Executive Officer of LB Pharmaceuticals Inc. (Nasdaq: LBRX), a clinical stage biopharmaceutical company since November 2024. Prior to joining LB Pharmaceuticals, Ms. Turner was President and Chief Executive Officer of Carmot Therapeutics Inc., or Carmot (acquired by Roche) from January 2023 to June 2024 and Chief Operating Officer from September 2022 to December 2022. Prior to Carmot, Ms. Turner served as Chief Legal Officer at Lyell Immunopharma, Inc. from April 2019 to May 2022. Prior to Lyell, Ms. Turner served as Executive Vice President, General Counsel and Secretary of Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a publicly traded gene therapy and gene editing company, from February 2018 to March 2019, and served as Executive Vice President, General Counsel, Secretary, and Head of Portfolio Strategy at Atara Biotherapeutics, Inc. (Nasdaq: ATRA), or Atara, a publicly traded allogeneic cell therapy company, from September 2016 to February 2018 and as Vice President and General Counsel of Atara from June 2015 to September 2016. Prior to that, Ms. Turner served as General Counsel and Secretary at Orexigen Therapeutics, Inc. a company focused on metabolic diseases, from June 2007 to June 2015. Ms. Turner has served as a member of the board of directors of Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical stage biopharmaceutical company, since November 2024. Ms. Turner started her career at Cooley LLP as a corporate securities associate. Ms. Turner received her J.D. from UCLA School of Law and her B.A. in Environmental Studies from the University of California, Santa Barbara.
- Kate Haviland
-
Kate Haviland自2018年6月以来一直担任我们的董事会成员。Haviland女士自2019年2月起担任精密治疗公司蓝图医药公司（Blueprint）的首席运营官。在担任首席运营官之前，Haviland女士于2016年1月至2019年1月担任Blueprint的首席商务官。在此之前，Haviland从2014年4月到2015年12月担任iDera Vice President、罕见病和肿瘤项目负责人，iDera是一家处于临床阶段的生物制药公司，她在该公司负责iDera罕见病和肿瘤项目产品开发战略的各个方面，包括临床前研究，制造和药物供应，法规事务，临床开发和执行以及商业计划。在加入IDERA之前，Haviland女士于2012年6月至2014年4月担任SareptaTherapeutics，Inc.（一家商业阶段的生物制药公司）的商业开发主管，在那里她负责产品开发和商业计划，并培养与关键意见领袖和患者倡导团体的关系。此外，Haviland女士曾于2007年3月至2012年6月担任生物制药公司PtcTherapeutics，Inc.的商业开发执行董事，并于2005年7月至2007年4月在生物技术公司Genzyme担任公司开发和项目管理职务。Haviland女士在卫斯理大学（Wesleyan University）获得生物化学/分子生物学和经济学双专业学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Kate Haviland has been a member of Avalyn Pharma Inc.'s board of directors since March 2026. Ms. Haviland has most recently served as President and Chief Executive Officer of Blueprint Medicines Corporation (formerly Nasdaq: BPMC), or Blueprint, a clinical stage biopharmaceutical company, from April 2022 through SANOFI's acquisition of Blueprint in July 2025. Prior to serving as President and Chief Executive Officer, Ms. Haviland served as Chief Operating Officer of Blueprint from January 2019 to April 2022 and as Chief Business Officer from January 2016 to January 2019. Prior to joining Blueprint, Ms. Haviland served as vice president, rare diseases and oncology program leadership at Idera Pharmaceuticals, Inc. (acquired by Aceragen, Inc.), a biopharmaceutical company, from April 2014 to December 2015, as head of commercial development at Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a public biopharmaceutical and drug development company, from June 2012 to April 2014, as executive director of commercial development at PTC Therapeutics, Inc. (Nasdaq: PTCT), a public biopharmaceutical company, from March 2007 to June 2012, and roles in corporate development and project management at Genzyme, Inc. (acquired by SANOFI, a global healthcare company) from July 2005 to March 2007. Ms. Haviland has served on the board of directors of Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a public biopharmaceutical company, since June 2018 and as chair of the board of directors since January 2022. Ms. Haviland has also served on the board of directors of Bicara Therapeutics Inc. (Nasdaq: BCAX), a public biotechnology company, since September 2023 and has served as chair of the board of directors of GC Therapeutics, Inc., a private biopharmaceutical company, since December 2025. Ms. Haviland received her M.B.A. from Harvard Business School and her B.A. in Biochemistry/Molecular Biology and Economics from Wesleyan University. - Kate Haviland自2018年6月以来一直担任我们的董事会成员。Haviland女士自2019年2月起担任精密治疗公司蓝图医药公司（Blueprint）的首席运营官。在担任首席运营官之前，Haviland女士于2016年1月至2019年1月担任Blueprint的首席商务官。在此之前，Haviland从2014年4月到2015年12月担任iDera Vice President、罕见病和肿瘤项目负责人，iDera是一家处于临床阶段的生物制药公司，她在该公司负责iDera罕见病和肿瘤项目产品开发战略的各个方面，包括临床前研究，制造和药物供应，法规事务，临床开发和执行以及商业计划。在加入IDERA之前，Haviland女士于2012年6月至2014年4月担任SareptaTherapeutics，Inc.（一家商业阶段的生物制药公司）的商业开发主管，在那里她负责产品开发和商业计划，并培养与关键意见领袖和患者倡导团体的关系。此外，Haviland女士曾于2007年3月至2012年6月担任生物制药公司PtcTherapeutics，Inc.的商业开发执行董事，并于2005年7月至2007年4月在生物技术公司Genzyme担任公司开发和项目管理职务。Haviland女士在卫斯理大学（Wesleyan University）获得生物化学/分子生物学和经济学双专业学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Kate Haviland has been a member of Avalyn Pharma Inc.'s board of directors since March 2026. Ms. Haviland has most recently served as President and Chief Executive Officer of Blueprint Medicines Corporation (formerly Nasdaq: BPMC), or Blueprint, a clinical stage biopharmaceutical company, from April 2022 through SANOFI's acquisition of Blueprint in July 2025. Prior to serving as President and Chief Executive Officer, Ms. Haviland served as Chief Operating Officer of Blueprint from January 2019 to April 2022 and as Chief Business Officer from January 2016 to January 2019. Prior to joining Blueprint, Ms. Haviland served as vice president, rare diseases and oncology program leadership at Idera Pharmaceuticals, Inc. (acquired by Aceragen, Inc.), a biopharmaceutical company, from April 2014 to December 2015, as head of commercial development at Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a public biopharmaceutical and drug development company, from June 2012 to April 2014, as executive director of commercial development at PTC Therapeutics, Inc. (Nasdaq: PTCT), a public biopharmaceutical company, from March 2007 to June 2012, and roles in corporate development and project management at Genzyme, Inc. (acquired by SANOFI, a global healthcare company) from July 2005 to March 2007. Ms. Haviland has served on the board of directors of Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a public biopharmaceutical company, since June 2018 and as chair of the board of directors since January 2022. Ms. Haviland has also served on the board of directors of Bicara Therapeutics Inc. (Nasdaq: BCAX), a public biotechnology company, since September 2023 and has served as chair of the board of directors of GC Therapeutics, Inc., a private biopharmaceutical company, since December 2025. Ms. Haviland received her M.B.A. from Harvard Business School and her B.A. in Biochemistry/Molecular Biology and Economics from Wesleyan University.
- Erin Lavelle
-
Erin Lavelle自2020年10月起担任首席运营官兼首席财务官Eliem Therapeutics，这是一家总部位于西雅图的私营神经治疗公司。Lavelle女士于2018年4月至2020年2月担任AlderBiopharmaceuticals，Inc.首席运营官此外，她曾担任Vitaeris公司（私人生物技术公司，位于加拿大British Columbia温哥华）的Alder公司的任命董事。在此之前，她于2003年至2018年在安进公司担任过各种职务，最近于2017年9月至2018年4月担任台湾总经理，于2016年5月至2017年9月担任日本亚太香港执行董事，2014年6月至2016年5月的全球营销业务分析和见解。她的职业生涯始于美林投资银行。Lavelle女士拥有耶鲁大学经济学学士学位。
Erin Lavelle has been a member of Avalyn Pharma Inc.'s board of directors since July 2024. From October 2023 until July 2024, Ms. Lavelle served as the Chief Operating Officer and Chief Financial Officer at ProfoundBio, Inc., a private biotechnology company that was acquired by Genmab A/S in May 2024. Prior to ProfoundBio, Ms. Lavelle served as Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) (Nasdaq: CLYM), a biotechnology company, from October 2020 to March 2023, where she assisted with the company's IPO. From April 2018 to February 2020, Ms. Lavelle served as the Chief Operating Officer at Alder BioPharmaceuticals, Inc., or AlderBio, a Nasdaq listed biotechnology company that was acquired by H. Lundbeck A/S in October 2019. In addition to that role, she served as Alder's appointed director for Vitaeris Inc., a privately held biotechnology company based in Vancouver, British Columbia, Canada. Prior to that, Ms. Lavelle served in various roles at Amgen Inc. (Nasdaq: AMGN) from 2003 to 2018, most recently serving as General Manager Taiwan from September 2017 to April 2018, as Executive Director, Japan Asia Pacific (Hong Kong) from May 2016 to September 2017, and Executive Director, Global Marketing Business Analytics and Insights from June 2014 to May 2016. Ms. Lavelle has a decade of M&A and licensing experience at Amgen and also led negotiations for the successful sales of two companies (AlderBio and ProfoundBio). She started her career as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle currently serves as a member of several private company boards of directors. She has served as a member of the board of directors of Jade Biosciences, Inc. (Nasdaq: JADE) since September 2024 and served as a member of the board of directors of Neoleukin Therapeutics, Inc., a Nasdaq listed biopharmaceutical company, which later became Neurogene Inc. (Nasdaq: NGNE), from May 2020 to December 2023. Ms. Lavelle holds a B.A. in economics from Yale University. - Erin Lavelle自2020年10月起担任首席运营官兼首席财务官Eliem Therapeutics，这是一家总部位于西雅图的私营神经治疗公司。Lavelle女士于2018年4月至2020年2月担任AlderBiopharmaceuticals，Inc.首席运营官此外，她曾担任Vitaeris公司（私人生物技术公司，位于加拿大British Columbia温哥华）的Alder公司的任命董事。在此之前，她于2003年至2018年在安进公司担任过各种职务，最近于2017年9月至2018年4月担任台湾总经理，于2016年5月至2017年9月担任日本亚太香港执行董事，2014年6月至2016年5月的全球营销业务分析和见解。她的职业生涯始于美林投资银行。Lavelle女士拥有耶鲁大学经济学学士学位。
- Erin Lavelle has been a member of Avalyn Pharma Inc.'s board of directors since July 2024. From October 2023 until July 2024, Ms. Lavelle served as the Chief Operating Officer and Chief Financial Officer at ProfoundBio, Inc., a private biotechnology company that was acquired by Genmab A/S in May 2024. Prior to ProfoundBio, Ms. Lavelle served as Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) (Nasdaq: CLYM), a biotechnology company, from October 2020 to March 2023, where she assisted with the company's IPO. From April 2018 to February 2020, Ms. Lavelle served as the Chief Operating Officer at Alder BioPharmaceuticals, Inc., or AlderBio, a Nasdaq listed biotechnology company that was acquired by H. Lundbeck A/S in October 2019. In addition to that role, she served as Alder's appointed director for Vitaeris Inc., a privately held biotechnology company based in Vancouver, British Columbia, Canada. Prior to that, Ms. Lavelle served in various roles at Amgen Inc. (Nasdaq: AMGN) from 2003 to 2018, most recently serving as General Manager Taiwan from September 2017 to April 2018, as Executive Director, Japan Asia Pacific (Hong Kong) from May 2016 to September 2017, and Executive Director, Global Marketing Business Analytics and Insights from June 2014 to May 2016. Ms. Lavelle has a decade of M&A and licensing experience at Amgen and also led negotiations for the successful sales of two companies (AlderBio and ProfoundBio). She started her career as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle currently serves as a member of several private company boards of directors. She has served as a member of the board of directors of Jade Biosciences, Inc. (Nasdaq: JADE) since September 2024 and served as a member of the board of directors of Neoleukin Therapeutics, Inc., a Nasdaq listed biopharmaceutical company, which later became Neurogene Inc. (Nasdaq: NGNE), from May 2020 to December 2023. Ms. Lavelle holds a B.A. in economics from Yale University.
- David Friedman
-
David Friedman自2025年12月起担任董事会成员。自2020年1月起，弗里德曼博士担任Suvretta Capital Management，LLC或Suvretta Capital的董事总经理和高级分析师。在加入Suvretta Capital之前，Friedman博士曾担任Scopia Capital Management LP的医疗保健分析师，并曾在摩根士丹利 & Co. LLC从事生物技术股票研究工作。弗里德曼博士在杜克大学获得生物学学士学位，在匹兹堡大学医学院获得医学博士学位，在哈佛大学比尼斯学院获得工商管理硕士学位。
David Friedman has been a member of Avalyn Pharma Inc.'s board of directors since April 2025. Since January 2020, Dr. Friedman has served as a Managing Director and Senior Analyst at Suvretta Capital Management, LLC, or Suvretta, for its healthcare and biotech focused Averill investment strategies. Prior to Suvretta, Dr. Friedman was a Healthcare Analyst at Scopia Capital Management from the beginning of 2014 to December 2019 and worked in biotechnology equity research at Morgan Stanley from 2006 to 2009 and 2010 to 2014. Dr. Friedman currently serves on the board of directors of Veradermics, Inc. (Nasdaq: MANE), Click Therapeutics, Inc., and Sapphiros. Dr. Friedman received an M.B.A. from Harvard Business School, an M.D. from University of Pittsburgh School of Medicine and a B.S. from Duke University in Biology. - David Friedman自2025年12月起担任董事会成员。自2020年1月起，弗里德曼博士担任Suvretta Capital Management，LLC或Suvretta Capital的董事总经理和高级分析师。在加入Suvretta Capital之前，Friedman博士曾担任Scopia Capital Management LP的医疗保健分析师，并曾在摩根士丹利 & Co. LLC从事生物技术股票研究工作。弗里德曼博士在杜克大学获得生物学学士学位，在匹兹堡大学医学院获得医学博士学位，在哈佛大学比尼斯学院获得工商管理硕士学位。
- David Friedman has been a member of Avalyn Pharma Inc.'s board of directors since April 2025. Since January 2020, Dr. Friedman has served as a Managing Director and Senior Analyst at Suvretta Capital Management, LLC, or Suvretta, for its healthcare and biotech focused Averill investment strategies. Prior to Suvretta, Dr. Friedman was a Healthcare Analyst at Scopia Capital Management from the beginning of 2014 to December 2019 and worked in biotechnology equity research at Morgan Stanley from 2006 to 2009 and 2010 to 2014. Dr. Friedman currently serves on the board of directors of Veradermics, Inc. (Nasdaq: MANE), Click Therapeutics, Inc., and Sapphiros. Dr. Friedman received an M.B.A. from Harvard Business School, an M.D. from University of Pittsburgh School of Medicine and a B.S. from Duke University in Biology.
- Lyn Baranowski
-
Lyn Baranowski自2022年10月起担任Avalyn Pharma Inc.总裁兼首席执行官，并担任Avalyn Pharma Inc.董事会成员。在加入Avalyn Pharma Inc.之前，Baranowski女士曾担任Altavant的首席运营官，自2018年10月成立至2022年10月。在Altavant，Baranowski女士负责监督罕见呼吸道疾病疗法的开发，并为该公司在2019年被Sumitomo Dainippon以30亿美元收购做出了贡献。在加入Altavant之前，Baranowski女士于2013年8月至2018年7月在Melinta Therapeutics，LLC（前身为纳斯达克：MLNT）担任企业发展与战略高级副总裁。2011年5月至2013年8月，Baranowski女士担任Pearl Therapeutics，Inc.的商业发展副总裁，该公司成功开发了吸入呼吸道药物组合，导致其被阿斯利康以11.5亿美元收购。Baranowski女士还曾在纽约一家专注于医疗保健的风险投资公司担任副总裁，并在美国和瑞士的诺华制药公司担任业务发展、市场营销和公共事务方面的高级职务。Baranowski女士于2021年11月至2023年5月期间担任Rani Therapeutics Holdings, Inc.（纳斯达克：RANI）的董事会成员，并担任Life Science Cares的顾问委员会成员，并且是美国胸科学会呼吸创新峰会规划委员会的重要成员。巴拉诺夫斯基女士拥有哈佛商学院的工商管理硕士学位和美国大学的学士学位。
Lyn Baranowski has served as Avalyn Pharma Inc.'s President and Chief Executive Officer and as a member of Avalyn Pharma Inc.'s board of directors since October 2022. Prior to joining Avalyn Pharma Inc., Ms. Baranowski served as Chief Operating Officer of Altavant, from its formation in October 2018 until October 2022. At Altavant, Ms. Baranowski oversaw the development of therapies for rare respiratory diseases and contributed to the company's $3 billion acquisition by Sumitomo Dainippon in 2019. Prior to Altavant, Ms. Baranowski served as Senior Vice President, Corporate Development & Strategy at Melinta Therapeutics, LLC (formerly, Nasdaq: MLNT) from August 2013 to July 2018. From May 2011 to August 2013, Ms. Baranowski served as Vice President of Commercial Development at Pearl Therapeutics, Inc., which successfully developed a portfolio of inhaled respiratory medicines that led to its $1.15 billion acquisition by AstraZeneca. Ms. Baranowski also served as Vice President at a healthcare focused venture capital firm based in New York, and served in senior roles in business development, marketing, and public affairs at Novartis Pharmaceuticals in both the U.S. and Switzerland. Throughout her career, Ms. Baranowski has played pivotal roles in the development and commercialization of market shaping therapies, including BREZTRI, BEVESPI, XOLAIR, TOBI, RECLAST, and BAXDELA, and has helped companies she worked for raise over $750 million in private and public financings. Ms. Baranowski served as a member of the Board of Directors of Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) from November 2021 to May 2023 and serves on the Board of Advisors for Life Science Cares and is a key member of the planning committee for the American Thoracic Society's Respiratory Innovation Summit. Ms. Baranowski holds an M.B.A. from Harvard Business School and a B.A. from American University. - Lyn Baranowski自2022年10月起担任Avalyn Pharma Inc.总裁兼首席执行官，并担任Avalyn Pharma Inc.董事会成员。在加入Avalyn Pharma Inc.之前，Baranowski女士曾担任Altavant的首席运营官，自2018年10月成立至2022年10月。在Altavant，Baranowski女士负责监督罕见呼吸道疾病疗法的开发，并为该公司在2019年被Sumitomo Dainippon以30亿美元收购做出了贡献。在加入Altavant之前，Baranowski女士于2013年8月至2018年7月在Melinta Therapeutics，LLC（前身为纳斯达克：MLNT）担任企业发展与战略高级副总裁。2011年5月至2013年8月，Baranowski女士担任Pearl Therapeutics，Inc.的商业发展副总裁，该公司成功开发了吸入呼吸道药物组合，导致其被阿斯利康以11.5亿美元收购。Baranowski女士还曾在纽约一家专注于医疗保健的风险投资公司担任副总裁，并在美国和瑞士的诺华制药公司担任业务发展、市场营销和公共事务方面的高级职务。Baranowski女士于2021年11月至2023年5月期间担任Rani Therapeutics Holdings, Inc.（纳斯达克：RANI）的董事会成员，并担任Life Science Cares的顾问委员会成员，并且是美国胸科学会呼吸创新峰会规划委员会的重要成员。巴拉诺夫斯基女士拥有哈佛商学院的工商管理硕士学位和美国大学的学士学位。
- Lyn Baranowski has served as Avalyn Pharma Inc.'s President and Chief Executive Officer and as a member of Avalyn Pharma Inc.'s board of directors since October 2022. Prior to joining Avalyn Pharma Inc., Ms. Baranowski served as Chief Operating Officer of Altavant, from its formation in October 2018 until October 2022. At Altavant, Ms. Baranowski oversaw the development of therapies for rare respiratory diseases and contributed to the company's $3 billion acquisition by Sumitomo Dainippon in 2019. Prior to Altavant, Ms. Baranowski served as Senior Vice President, Corporate Development & Strategy at Melinta Therapeutics, LLC (formerly, Nasdaq: MLNT) from August 2013 to July 2018. From May 2011 to August 2013, Ms. Baranowski served as Vice President of Commercial Development at Pearl Therapeutics, Inc., which successfully developed a portfolio of inhaled respiratory medicines that led to its $1.15 billion acquisition by AstraZeneca. Ms. Baranowski also served as Vice President at a healthcare focused venture capital firm based in New York, and served in senior roles in business development, marketing, and public affairs at Novartis Pharmaceuticals in both the U.S. and Switzerland. Throughout her career, Ms. Baranowski has played pivotal roles in the development and commercialization of market shaping therapies, including BREZTRI, BEVESPI, XOLAIR, TOBI, RECLAST, and BAXDELA, and has helped companies she worked for raise over $750 million in private and public financings. Ms. Baranowski served as a member of the Board of Directors of Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) from November 2021 to May 2023 and serves on the Board of Advisors for Life Science Cares and is a key member of the planning committee for the American Thoracic Society's Respiratory Innovation Summit. Ms. Baranowski holds an M.B.A. from Harvard Business School and a B.A. from American University.
- Jill Carroll
-
Jill Carroll，2013年4月以来，她一直担任公司的董事会的成员。她曾一直担任S.R.One, Limited公司（GlaxoSmithKline公司的企业风险资本分公司）的高级职务（2011年9月以来）。任职S.R.One, Limited公司之前，她曾担任Dynavax Technologies Corporation（生物制药公司）的负责公司发展的高级主管（从2004年5月到2010年8月）、Limerick Biopharma公司（制药公司）的公司发展副总裁（从2010年8月到2011年9月）。她也曾担任Clearview Projects公司（咨询公司）（从2001年10月到2004年5月）和Mercer Management Consulting公司（从1999年3月到2001年7月）的顾问。她持有杜克大学（Duke University）的化学学士学位，以及约翰·霍普金斯大学（Johns Hopkins University）的生物化学、细胞和分子生物学硕士学位。
Jill Carroll has been a member of Avalyn Pharma Inc.'s board of directors since September 2023. Ms. Carroll joined S.R. One Ltd in 2011 and SR One Capital Management, LP in 2020 with a background in biotech partnering and corporate development. Previously, Ms. Carroll completed multiple pharma partnerships and substantial private and public financings for Dynavax Technologies (Nasdaq: DVAX) as the Senior Director, Strategic Planning & Corporate Development. Ms. Carroll was formerly a biopharmaceutical industry consultant with Clearview Projects and Mercer Management Consulting. Currently, Ms. Carroll is on the boards of directors of Arcellx, Inc. (Nasdaq: ACLX), HotSpot Therapeutics, Inc., TBIO, LLC, Odyssey Therapeutics, Inc., Poplar Therapeutics, Inc., and AirNexis Therapeutics, Inc., and previously served on the board of Nkarta, Inc. (Nasdaq: NKTX) from 2017 to 2020. Ms. Carroll received her B.S. in Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University. - Jill Carroll，2013年4月以来，她一直担任公司的董事会的成员。她曾一直担任S.R.One, Limited公司（GlaxoSmithKline公司的企业风险资本分公司）的高级职务（2011年9月以来）。任职S.R.One, Limited公司之前，她曾担任Dynavax Technologies Corporation（生物制药公司）的负责公司发展的高级主管（从2004年5月到2010年8月）、Limerick Biopharma公司（制药公司）的公司发展副总裁（从2010年8月到2011年9月）。她也曾担任Clearview Projects公司（咨询公司）（从2001年10月到2004年5月）和Mercer Management Consulting公司（从1999年3月到2001年7月）的顾问。她持有杜克大学（Duke University）的化学学士学位，以及约翰·霍普金斯大学（Johns Hopkins University）的生物化学、细胞和分子生物学硕士学位。
- Jill Carroll has been a member of Avalyn Pharma Inc.'s board of directors since September 2023. Ms. Carroll joined S.R. One Ltd in 2011 and SR One Capital Management, LP in 2020 with a background in biotech partnering and corporate development. Previously, Ms. Carroll completed multiple pharma partnerships and substantial private and public financings for Dynavax Technologies (Nasdaq: DVAX) as the Senior Director, Strategic Planning & Corporate Development. Ms. Carroll was formerly a biopharmaceutical industry consultant with Clearview Projects and Mercer Management Consulting. Currently, Ms. Carroll is on the boards of directors of Arcellx, Inc. (Nasdaq: ACLX), HotSpot Therapeutics, Inc., TBIO, LLC, Odyssey Therapeutics, Inc., Poplar Therapeutics, Inc., and AirNexis Therapeutics, Inc., and previously served on the board of Nkarta, Inc. (Nasdaq: NKTX) from 2017 to 2020. Ms. Carroll received her B.S. in Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.
高管简历
中英对照 | 中文 | 英文- Lyn Baranowski
Lyn Baranowski自2022年10月起担任Avalyn Pharma Inc.总裁兼首席执行官，并担任Avalyn Pharma Inc.董事会成员。在加入Avalyn Pharma Inc.之前，Baranowski女士曾担任Altavant的首席运营官，自2018年10月成立至2022年10月。在Altavant，Baranowski女士负责监督罕见呼吸道疾病疗法的开发，并为该公司在2019年被Sumitomo Dainippon以30亿美元收购做出了贡献。在加入Altavant之前，Baranowski女士于2013年8月至2018年7月在Melinta Therapeutics，LLC（前身为纳斯达克：MLNT）担任企业发展与战略高级副总裁。2011年5月至2013年8月，Baranowski女士担任Pearl Therapeutics，Inc.的商业发展副总裁，该公司成功开发了吸入呼吸道药物组合，导致其被阿斯利康以11.5亿美元收购。Baranowski女士还曾在纽约一家专注于医疗保健的风险投资公司担任副总裁，并在美国和瑞士的诺华制药公司担任业务发展、市场营销和公共事务方面的高级职务。Baranowski女士于2021年11月至2023年5月期间担任Rani Therapeutics Holdings, Inc.（纳斯达克：RANI）的董事会成员，并担任Life Science Cares的顾问委员会成员，并且是美国胸科学会呼吸创新峰会规划委员会的重要成员。巴拉诺夫斯基女士拥有哈佛商学院的工商管理硕士学位和美国大学的学士学位。
Lyn Baranowski has served as Avalyn Pharma Inc.'s President and Chief Executive Officer and as a member of Avalyn Pharma Inc.'s board of directors since October 2022. Prior to joining Avalyn Pharma Inc., Ms. Baranowski served as Chief Operating Officer of Altavant, from its formation in October 2018 until October 2022. At Altavant, Ms. Baranowski oversaw the development of therapies for rare respiratory diseases and contributed to the company's $3 billion acquisition by Sumitomo Dainippon in 2019. Prior to Altavant, Ms. Baranowski served as Senior Vice President, Corporate Development & Strategy at Melinta Therapeutics, LLC (formerly, Nasdaq: MLNT) from August 2013 to July 2018. From May 2011 to August 2013, Ms. Baranowski served as Vice President of Commercial Development at Pearl Therapeutics, Inc., which successfully developed a portfolio of inhaled respiratory medicines that led to its $1.15 billion acquisition by AstraZeneca. Ms. Baranowski also served as Vice President at a healthcare focused venture capital firm based in New York, and served in senior roles in business development, marketing, and public affairs at Novartis Pharmaceuticals in both the U.S. and Switzerland. Throughout her career, Ms. Baranowski has played pivotal roles in the development and commercialization of market shaping therapies, including BREZTRI, BEVESPI, XOLAIR, TOBI, RECLAST, and BAXDELA, and has helped companies she worked for raise over $750 million in private and public financings. Ms. Baranowski served as a member of the Board of Directors of Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) from November 2021 to May 2023 and serves on the Board of Advisors for Life Science Cares and is a key member of the planning committee for the American Thoracic Society's Respiratory Innovation Summit. Ms. Baranowski holds an M.B.A. from Harvard Business School and a B.A. from American University.- Lyn Baranowski自2022年10月起担任Avalyn Pharma Inc.总裁兼首席执行官，并担任Avalyn Pharma Inc.董事会成员。在加入Avalyn Pharma Inc.之前，Baranowski女士曾担任Altavant的首席运营官，自2018年10月成立至2022年10月。在Altavant，Baranowski女士负责监督罕见呼吸道疾病疗法的开发，并为该公司在2019年被Sumitomo Dainippon以30亿美元收购做出了贡献。在加入Altavant之前，Baranowski女士于2013年8月至2018年7月在Melinta Therapeutics，LLC（前身为纳斯达克：MLNT）担任企业发展与战略高级副总裁。2011年5月至2013年8月，Baranowski女士担任Pearl Therapeutics，Inc.的商业发展副总裁，该公司成功开发了吸入呼吸道药物组合，导致其被阿斯利康以11.5亿美元收购。Baranowski女士还曾在纽约一家专注于医疗保健的风险投资公司担任副总裁，并在美国和瑞士的诺华制药公司担任业务发展、市场营销和公共事务方面的高级职务。Baranowski女士于2021年11月至2023年5月期间担任Rani Therapeutics Holdings, Inc.（纳斯达克：RANI）的董事会成员，并担任Life Science Cares的顾问委员会成员，并且是美国胸科学会呼吸创新峰会规划委员会的重要成员。巴拉诺夫斯基女士拥有哈佛商学院的工商管理硕士学位和美国大学的学士学位。
- Lyn Baranowski has served as Avalyn Pharma Inc.'s President and Chief Executive Officer and as a member of Avalyn Pharma Inc.'s board of directors since October 2022. Prior to joining Avalyn Pharma Inc., Ms. Baranowski served as Chief Operating Officer of Altavant, from its formation in October 2018 until October 2022. At Altavant, Ms. Baranowski oversaw the development of therapies for rare respiratory diseases and contributed to the company's $3 billion acquisition by Sumitomo Dainippon in 2019. Prior to Altavant, Ms. Baranowski served as Senior Vice President, Corporate Development & Strategy at Melinta Therapeutics, LLC (formerly, Nasdaq: MLNT) from August 2013 to July 2018. From May 2011 to August 2013, Ms. Baranowski served as Vice President of Commercial Development at Pearl Therapeutics, Inc., which successfully developed a portfolio of inhaled respiratory medicines that led to its $1.15 billion acquisition by AstraZeneca. Ms. Baranowski also served as Vice President at a healthcare focused venture capital firm based in New York, and served in senior roles in business development, marketing, and public affairs at Novartis Pharmaceuticals in both the U.S. and Switzerland. Throughout her career, Ms. Baranowski has played pivotal roles in the development and commercialization of market shaping therapies, including BREZTRI, BEVESPI, XOLAIR, TOBI, RECLAST, and BAXDELA, and has helped companies she worked for raise over $750 million in private and public financings. Ms. Baranowski served as a member of the Board of Directors of Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) from November 2021 to May 2023 and serves on the Board of Advisors for Life Science Cares and is a key member of the planning committee for the American Thoracic Society's Respiratory Innovation Summit. Ms. Baranowski holds an M.B.A. from Harvard Business School and a B.A. from American University.
- Howard M. Lazarus
Howard M. Lazarus自2023年8月起担任Avalyn Pharma Inc.的首席医疗官。Lazarus博士曾于2022年12月至2023年7月担任Enzyvant Therapeutics，Inc.的首席医疗官，并于2019年被Sumitomo Dainippon收购后于2020年2月至2022年11月担任Altavant的首席医疗官。在担任这一职务时，他负责为解决肺动脉高压和慢性同种异体肺移植功能障碍的候选者制定和实施临床开发计划。在加入Altavant之前，Lazarus博士曾在勃林格殷格翰和吉利德科学的临床开发和医疗事务团队担任高级职务。拉扎鲁斯博士拥有麦吉尔大学的理学学士和医学博士学位，他在波士顿大学完成了内科培训。他的肺部和重症医学研究金培训是在加州大学圣地亚哥分校获得的。他是美国胸科医师学院的研究员，也是美国胸科和欧洲呼吸系统学会的成员。
Howard M. Lazarus has served as Avalyn Pharma Inc.'s Chief Medical Officer since August 2023. Dr. Lazarus formerly served as the Chief Medical Officer of Enzyvant Therapeutics, Inc. from December 2022 to July 2023, and Chief Medical Officer of Altavant from February 2020 to November 2022, after its acquisition by Sumitomo Dainippon in 2019. In this role, he was responsible for developing and implementing the clinical development plans for candidates addressing pulmonary arterial hypertension and chronic lung allograft dysfunction. Prior to Altavant, Dr. Lazarus has held senior roles in clinical development and medical affairs teams at Boehringer Ingelheim and Gilead Sciences. Dr. Lazarus holds a B.Sc. and an M.D. from McGill University and he completed his internal medicine training at Boston University. His fellowship training in pulmonary and critical care medicine was obtained at the University of California, San Diego. He is a fellow of the American College of Chest Physicians and a member of the American Thoracic and European Respiratory Societies.- Howard M. Lazarus自2023年8月起担任Avalyn Pharma Inc.的首席医疗官。Lazarus博士曾于2022年12月至2023年7月担任Enzyvant Therapeutics，Inc.的首席医疗官，并于2019年被Sumitomo Dainippon收购后于2020年2月至2022年11月担任Altavant的首席医疗官。在担任这一职务时，他负责为解决肺动脉高压和慢性同种异体肺移植功能障碍的候选者制定和实施临床开发计划。在加入Altavant之前，Lazarus博士曾在勃林格殷格翰和吉利德科学的临床开发和医疗事务团队担任高级职务。拉扎鲁斯博士拥有麦吉尔大学的理学学士和医学博士学位，他在波士顿大学完成了内科培训。他的肺部和重症医学研究金培训是在加州大学圣地亚哥分校获得的。他是美国胸科医师学院的研究员，也是美国胸科和欧洲呼吸系统学会的成员。
- Howard M. Lazarus has served as Avalyn Pharma Inc.'s Chief Medical Officer since August 2023. Dr. Lazarus formerly served as the Chief Medical Officer of Enzyvant Therapeutics, Inc. from December 2022 to July 2023, and Chief Medical Officer of Altavant from February 2020 to November 2022, after its acquisition by Sumitomo Dainippon in 2019. In this role, he was responsible for developing and implementing the clinical development plans for candidates addressing pulmonary arterial hypertension and chronic lung allograft dysfunction. Prior to Altavant, Dr. Lazarus has held senior roles in clinical development and medical affairs teams at Boehringer Ingelheim and Gilead Sciences. Dr. Lazarus holds a B.Sc. and an M.D. from McGill University and he completed his internal medicine training at Boston University. His fellowship training in pulmonary and critical care medicine was obtained at the University of California, San Diego. He is a fellow of the American College of Chest Physicians and a member of the American Thoracic and European Respiratory Societies.
- Douglas Carlson
Douglas Carlson自2024年5月起担任Avalyn Pharma Inc.的首席财务官和首席商务官。在加入Avalyn Pharma Inc.之前，Carlson先生于2022年2月至2024年5月期间担任Avenge Bio，Inc.的首席运营和财务官。在此之前，他于2021年2月至2022年2月担任Ikena Oncology, Inc.（Ikena Oncology，Inc.）或Ikena（纳斯达克：IKNA）的首席运营和财务官，并于2019年1月至2021年2月担任首席财务官。在加入Ikena之前，Carlson先生在Collegium制药（纳斯达克：COLL）担任越来越多的职务，包括从2013年3月至2019年1月担任负责商业运营、公司战略与业务发展的副总裁。在加入Collegium之前，Carlson先生于2011年8月至2013年3月在BTG International，Inc.（LSE：BTG）或BTG（一家上市的国际专业医疗保健公司）担任业务发展高级总监，负责全球专业制药并购和许可事务。在加入BTG之前，Carlson先生于2009年12月至2011年8月担任H. Lundbeck A/S的美国总部Lundbeck Inc.的高级董事兼业务发展主管。在加入Lundbeck之前，Carlson先生是Ovation Pharmaceuticals，Inc.或Ovation的企业发展和并购总监，在2009年3月将Ovation出售给H. Lundbeck A/S的过程中，他发挥了不可或缺的作用。在加入Ovation之前，Carlson先生是Pequot Capital Management，Inc.的风险投资部门Pequot Ventures的医疗保健集团的合伙人。Carlson先生的职业生涯始于高宏集团的医疗保健投资银行集团。卡尔森先生拥有康涅狄格州哈特福德三一学院的学士学位。
Douglas Carlson has served as Avalyn Pharma Inc.'s Chief Financial Officer and Chief Business Officer since May 2024. Prior to joining Avalyn Pharma Inc., Mr. Carlson served as the Chief Operating and Financial Officer of Avenge Bio, Inc. from February 2022 to May 2024. Prior to that, he served as Chief Operating and Financial Officer of Ikena Oncology, Inc., or Ikena, (Nasdaq: IKNA) from February 2021 to February 2022 and Chief Financial Officer from January 2019 to February 2021. Prior to Ikena, Mr. Carlson held roles of increasing responsibility at Collegium Pharmaceutical (Nasdaq: COLL), including as Vice President, Commercial Operations, Corporate Strategy & Business Development from March 2013 to January 2019. Prior to joining Collegium, Mr. Carlson was Senior Director of Business Development at BTG International, Inc. (LSE: BTG), or BTG, a publicly traded, international specialist healthcare company, where he was responsible for global specialty pharmaceutical M&A and licensing, from August 2011 to March 2013. Prior to BTG, Mr. Carlson was Senior Director and Head of Business Development for Lundbeck Inc., or Lundbeck, the U.S. Headquarters of H. Lundbeck A/S, from December 2009 to August 2011. Prior to Lundbeck, Mr. Carlson was Director of Corporate Development and M&A at Ovation Pharmaceuticals, Inc., or Ovation, where he played an integral role in the sale of Ovation to H. Lundbeck A/S in March 2009. Prior to Ovation, Mr. Carlson was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Mr. Carlson began his career in the healthcare investment banking group of Cowen. Mr. Carlson holds a B.A. from Trinity College in Hartford, Connecticut.- Douglas Carlson自2024年5月起担任Avalyn Pharma Inc.的首席财务官和首席商务官。在加入Avalyn Pharma Inc.之前，Carlson先生于2022年2月至2024年5月期间担任Avenge Bio，Inc.的首席运营和财务官。在此之前，他于2021年2月至2022年2月担任Ikena Oncology, Inc.（Ikena Oncology，Inc.）或Ikena（纳斯达克：IKNA）的首席运营和财务官，并于2019年1月至2021年2月担任首席财务官。在加入Ikena之前，Carlson先生在Collegium制药（纳斯达克：COLL）担任越来越多的职务，包括从2013年3月至2019年1月担任负责商业运营、公司战略与业务发展的副总裁。在加入Collegium之前，Carlson先生于2011年8月至2013年3月在BTG International，Inc.（LSE：BTG）或BTG（一家上市的国际专业医疗保健公司）担任业务发展高级总监，负责全球专业制药并购和许可事务。在加入BTG之前，Carlson先生于2009年12月至2011年8月担任H. Lundbeck A/S的美国总部Lundbeck Inc.的高级董事兼业务发展主管。在加入Lundbeck之前，Carlson先生是Ovation Pharmaceuticals，Inc.或Ovation的企业发展和并购总监，在2009年3月将Ovation出售给H. Lundbeck A/S的过程中，他发挥了不可或缺的作用。在加入Ovation之前，Carlson先生是Pequot Capital Management，Inc.的风险投资部门Pequot Ventures的医疗保健集团的合伙人。Carlson先生的职业生涯始于高宏集团的医疗保健投资银行集团。卡尔森先生拥有康涅狄格州哈特福德三一学院的学士学位。
- Douglas Carlson has served as Avalyn Pharma Inc.'s Chief Financial Officer and Chief Business Officer since May 2024. Prior to joining Avalyn Pharma Inc., Mr. Carlson served as the Chief Operating and Financial Officer of Avenge Bio, Inc. from February 2022 to May 2024. Prior to that, he served as Chief Operating and Financial Officer of Ikena Oncology, Inc., or Ikena, (Nasdaq: IKNA) from February 2021 to February 2022 and Chief Financial Officer from January 2019 to February 2021. Prior to Ikena, Mr. Carlson held roles of increasing responsibility at Collegium Pharmaceutical (Nasdaq: COLL), including as Vice President, Commercial Operations, Corporate Strategy & Business Development from March 2013 to January 2019. Prior to joining Collegium, Mr. Carlson was Senior Director of Business Development at BTG International, Inc. (LSE: BTG), or BTG, a publicly traded, international specialist healthcare company, where he was responsible for global specialty pharmaceutical M&A and licensing, from August 2011 to March 2013. Prior to BTG, Mr. Carlson was Senior Director and Head of Business Development for Lundbeck Inc., or Lundbeck, the U.S. Headquarters of H. Lundbeck A/S, from December 2009 to August 2011. Prior to Lundbeck, Mr. Carlson was Director of Corporate Development and M&A at Ovation Pharmaceuticals, Inc., or Ovation, where he played an integral role in the sale of Ovation to H. Lundbeck A/S in March 2009. Prior to Ovation, Mr. Carlson was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Mr. Carlson began his career in the healthcare investment banking group of Cowen. Mr. Carlson holds a B.A. from Trinity College in Hartford, Connecticut.
- Melissa Rhodes
Melissa Rhodes自2023年9月起担任Avalyn Pharma Inc.的首席运营官。在加入Avalyn Pharma Inc.之前，Rhodes博士曾于2020年2月至2023年7月在Kriya Therapeutics，Inc.担任多个职务，最近担任代谢疾病和神经病学总裁兼首席开发官。2019年2月至2020年2月，Rhodes博士担任Aerami Therapeutics，Inc.的首席开发官，该公司专注于吸入药物的交付。Rhodes博士在杜克大学完成了博士学位，专注于药理学和毒理学，是美国毒理学委员会的外交官，并获得了北卡罗来纳州立大学的学士学位。
Melissa Rhodes has served as Avalyn Pharma Inc.'s Chief Operating Officer since September 2023. Prior to joining Avalyn Pharma Inc., Dr. Rhodes served in various roles at Kriya Therapeutics, Inc. from February 2020 to July 2023, most recently as President & Chief Development Officer, Metabolic Diseases & Neurology. From February 2019 to February 2020, Dr. Rhodes served as Chief Development Officer at Aerami Therapeutics, Inc., which focused on the delivery of inhaled medicines. Dr. Rhodes completed her Ph.D. at Duke University, focusing on pharmacology and toxicology, and is a Diplomate of the American Board of Toxicology and received a B.S. from North Carolina State University.- Melissa Rhodes自2023年9月起担任Avalyn Pharma Inc.的首席运营官。在加入Avalyn Pharma Inc.之前，Rhodes博士曾于2020年2月至2023年7月在Kriya Therapeutics，Inc.担任多个职务，最近担任代谢疾病和神经病学总裁兼首席开发官。2019年2月至2020年2月，Rhodes博士担任Aerami Therapeutics，Inc.的首席开发官，该公司专注于吸入药物的交付。Rhodes博士在杜克大学完成了博士学位，专注于药理学和毒理学，是美国毒理学委员会的外交官，并获得了北卡罗来纳州立大学的学士学位。
- Melissa Rhodes has served as Avalyn Pharma Inc.'s Chief Operating Officer since September 2023. Prior to joining Avalyn Pharma Inc., Dr. Rhodes served in various roles at Kriya Therapeutics, Inc. from February 2020 to July 2023, most recently as President & Chief Development Officer, Metabolic Diseases & Neurology. From February 2019 to February 2020, Dr. Rhodes served as Chief Development Officer at Aerami Therapeutics, Inc., which focused on the delivery of inhaled medicines. Dr. Rhodes completed her Ph.D. at Duke University, focusing on pharmacology and toxicology, and is a Diplomate of the American Board of Toxicology and received a B.S. from North Carolina State University.
- Adam Golden
Adam Golden，自2026年4月起担任Avalyn Pharma Inc.总法律顾问。在加入Avalyn Pharma Inc.之前，Golden先生曾于2021年5月至2026年4月在全球领先的律师事务所Freshfields担任合伙人兼生命科学全球主管。在Freshfields，Golden先生创立并监督了国际公认的生命科学实践的建设。2014年2月至2021年5月，Golden先生在Hogan Lovells担任合伙人兼纽约企业业务组负责人。Golden先生在Kaye Scholer开始了他的职业生涯，在那里他度过了二十多年，并担任了越来越多的职责，包括公司部门的合伙人和联合主席。在其整个职业生涯中，Golden先生一直担任生物技术、制药和其他生命科学公司的战略法律和商业顾问，专注于并购、复杂的合作和其他变革性交易。Golden先生在Life Sciences Cares的顾问委员会任职。他拥有纽约大学法学院法学博士学位和普林斯顿大学化学学士学位。
Adam Golden has served as Avalyn Pharma Inc.'s General Counsel since April 2026. Prior to joining Avalyn Pharma Inc., Mr. Golden served as a Partner and Global Head of Life Sciences at Freshfields, a leading global law firm, from May 2021 to April 2026. At Freshfields, Mr. Golden founded and oversaw the build out of an internationally recognized life sciences practice. From February 2014 to May 2021, Mr. Golden served as a Partner and Head of the New York Corporate Practice Group at Hogan Lovells. Mr. Golden began his career at Kaye Scholer where he spent over twenty years and had roles of increasing responsibility, including Partner and Co Chair, Corporate Department. Throughout his career, Mr. Golden has served as a strategic legal and business adviser to biotechnology, pharmaceutical and other life sciences companies, with a focus on mergers and acquisitions, complex collaborations and other transformative transactions. Mr. Golden serves on the Board of Advisors of Life Sciences Cares. He holds a J.D. from New York University School of Law and an A.B. in Chemistry from Princeton University.- Adam Golden，自2026年4月起担任Avalyn Pharma Inc.总法律顾问。在加入Avalyn Pharma Inc.之前，Golden先生曾于2021年5月至2026年4月在全球领先的律师事务所Freshfields担任合伙人兼生命科学全球主管。在Freshfields，Golden先生创立并监督了国际公认的生命科学实践的建设。2014年2月至2021年5月，Golden先生在Hogan Lovells担任合伙人兼纽约企业业务组负责人。Golden先生在Kaye Scholer开始了他的职业生涯，在那里他度过了二十多年，并担任了越来越多的职责，包括公司部门的合伙人和联合主席。在其整个职业生涯中，Golden先生一直担任生物技术、制药和其他生命科学公司的战略法律和商业顾问，专注于并购、复杂的合作和其他变革性交易。Golden先生在Life Sciences Cares的顾问委员会任职。他拥有纽约大学法学院法学博士学位和普林斯顿大学化学学士学位。
- Adam Golden has served as Avalyn Pharma Inc.'s General Counsel since April 2026. Prior to joining Avalyn Pharma Inc., Mr. Golden served as a Partner and Global Head of Life Sciences at Freshfields, a leading global law firm, from May 2021 to April 2026. At Freshfields, Mr. Golden founded and oversaw the build out of an internationally recognized life sciences practice. From February 2014 to May 2021, Mr. Golden served as a Partner and Head of the New York Corporate Practice Group at Hogan Lovells. Mr. Golden began his career at Kaye Scholer where he spent over twenty years and had roles of increasing responsibility, including Partner and Co Chair, Corporate Department. Throughout his career, Mr. Golden has served as a strategic legal and business adviser to biotechnology, pharmaceutical and other life sciences companies, with a focus on mergers and acquisitions, complex collaborations and other transformative transactions. Mr. Golden serves on the Board of Advisors of Life Sciences Cares. He holds a J.D. from New York University School of Law and an A.B. in Chemistry from Princeton University.